A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

Table 1 Inclusion / exclusion criteria

Criteria	Inclusion	Exclusion
Patient population	Adults with progressive, locally advanced or metastatic, differentiated thyroid carcinoma, refractory to radioactive iodine	Patients with other types of thyroid cancer or diseases
Interventions	Lenvatinib or sorafenib monotherapy (or in combination with best supportive care)	Lenvatinib or sorafenib in combination with other agents
Comparators^a	Lenvatinib or sorafenib monotherapy (or in combination with best supportive care), best supportive care, placebo	A comparator other than lenvatinib, sorafenib, best supportive care, placebo
Outcomes	The outcome measures to be considered include: overall survival, progression-free survival, response rate, adverse effects of treatment, health-related quality of life	No study was excluded based on outcomes
Study design	Randomized controlled trials, systematic reviews,^b prospective observational studies	Retrospective cohort studies, case series, case reports, comments, letters, editorials, in vitro, animal, genetic or histochemical studies

^aWhere studies included a comparator arm
^bAt the inclusion stage, published reports of indirect comparisons were also included if the indirect comparison was based on RCT evidence, even if the conduct of a systematic review was not reported alongside the indirect comparison

ISSN: 1471-2407